Actively Recruiting

Phase 3
Age: 21Years - 80Years
All Genders
NCT07017634

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease

Led by CGBio Inc. · Updated on 2026-05-08

316

Participants Needed

5

Research Sites

287 weeks

Total Duration

On this page

Sponsors

C

CGBio Inc.

Lead Sponsor

C

CGBio USA

Collaborating Sponsor

AI-Summary

What this Trial Is About

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients with Lumbar Degenerative Disc Disease : A Pivotal, Randomized, Prospective, Multi-Center Study

CONDITIONS

Official Title

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease

Who Can Participate

Age: 21Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Primary diagnosis of symptomatic lumbar degeneration with or without foraminal or recess stenosis confirmed by history and imaging
  • No more than Grade 2 (≤50% translation) spondylolisthesis
  • History of failed conservative treatment for at least 6 months
  • Preoperative Oswestry Disability Index score of 40 or higher
  • Male or female aged 21 to 80 years, skeletally mature
  • Mentally and physically able to comply with study protocol and follow-up
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Previous instrumented surgery at the index or adjacent lumbar level
  • Degenerative or lytic spondylolisthesis greater than Grade 2 (50% translation)
  • Active invasive malignancy or history of malignancy within past 5 years (except non-melanoma skin cancer)
  • Degenerative muscular or neurological conditions interfering with outcome evaluation (e.g., Parkinson's disease, ALS, multiple sclerosis)
  • Chronic or acute kidney or liver impairment or history of related diseases
  • Lactating, pregnant, or planning pregnancy within 3 years
  • Participating in another investigational therapy within 30 days prior to study or during 24 months after enrollment
  • Known allergy or hypersensitivity to study treatment components including BMP-2 proteins or peptides

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

The Spine Center of Louisiana

Baton Rouge, Louisiana, United States, 70809

Actively Recruiting

2

LSU Health

Shreveport, Louisiana, United States, 71101

Actively Recruiting

3

Thomas Jefferson University - Department of Neurological Surgery

Philadelphia, Pennsylvania, United States, 19107

Actively Recruiting

4

American Neurospine Institute, PLLC

Frisco, Texas, United States, 75034

Actively Recruiting

5

West Virginia University - Department of Orthopaedics

Morgantown, West Virginia, United States, 26506

Actively Recruiting

Loading map...

Research Team

J

Jumi Han

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here